

# LVEDP: A Suggestive Predictor Of Mortality In Stemi Patients Undergoing Primary PCI



Dr. Mayank Sarawag<sup>1</sup>, Dr. Rakesh chaudhary<sup>2</sup>, Dr. Manju Bhaskar<sup>3\*</sup>

<sup>1</sup>Assistant Professor, Department of Cardiology, Jhalawar Medical College, Jhalawar, Rajasthan.

<sup>2</sup>Senior intervention Cardiologist, Krishna heart and Superspeciality centre, Jodhpur, Rajasthan.

<sup>3\*</sup>Professor and Head, Department of Psychiatry, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan.

## INTRODUCTION

Left ventricular end-diastolic pressure (LVEDP) is directly related to left ventricular (LV) compliance and intravascular volume and pressure, and one of the main consequences of LV diastolic dysfunction is increased LV Filling pressures.

In the context of coronary artery disease, elevated filling pressures can be caused by acute ischemia, an infarction scar, or myocardial hibernation.<sup>1,2,3,4,5</sup>

Acute ischemia results in an upward and rightward shift of the diastolic pressure-volume curve, which may be due to various factors: calcium overload in cardiomyocytes resulting in late activation and incomplete relaxation, pericardial constriction due to increased atrial and ventricular volume, intra and interventricular asynchrony and papillary muscle dysfunction.<sup>6,7,8</sup>

Variables known to affect prognosis in ST-segment elevation myocardial infarction (STEMI) include age, associated co-morbidities, infarct size and location, left ventricular systolic function, ventricular arrhythmias, ischemic mitral regurgitation, and cardiogenic shock. The prognostic utility of left ventricular ejection fraction (LVEF) measured during or after STEMI is also well established.<sup>9,10,11</sup>

However, although diastolic dysfunction precedes the onset of systolic dysfunction in acute ischemia, the prognostic utility of diastolic indexes in patients with STEMI has rarely been examined. Moreover, although left ventricular end diastolic filling pressure (LVEDP), which reflects global ventricular compliance, is routinely measured during left heart catheterization, no studies have evaluated the implications of LVEDP in patients with STEMI undergoing primary percutaneous coronary intervention (PCI).<sup>12,13,14,15,16,17</sup>

We therefore, have examine the prognostic value of LVEDP and the interrelation between LVEDP and LVEF as assessed during the primary PCI procedure in patients with STEMI.

## Aim and objectives-

- ☐ To predict mortality at 30 days and at 6 month among STEMI patients undergoing primary PCI on the basis of LVEDP.
- ☐ To find out correlation between LVEDP and EF in patients of STEMI undergoing primary PCI.

## Material and methods

**Study design:** Hospital based observational study.

**Setting:** Department of Cardiology, S.M.S Medical College, Jaipur.

**Study population:** 100 cases of STEMI patients undergoing primary PCI.

**Study period:-** 12 months

## Inclusion criteria:-

Patients with STEMI presenting to emergency department and to be taken up for primary PCI.

## Exclusion criteria:-

- ☐ Previous myocardial infarction
- ☐ Previous coronary angioplasty
- ☐ Previous coronary grafting
- ☐ Chronic heart failure
- ☐ LV clot

All patients with STEMI and to be taken up for primary PCI were enrolled in this study. Detailed history and risk factors were recorded. Routine physical and biochemical examinations were done for all patients in study. LVEDP was recorded just before coronary angiogram. LVEDP was measured at the Z-point, which is identified on the LV pressure trace as the point at which the slope of the ventricular pressure upstroke changes, which coincides with the R wave on the electrocardiographic tracing.

## STATISTICAL ANALYSIS-

Continuous is summarized in form of Mean  $\pm$  standard deviation.

Difference in the mean of two group is analyzed in form of student "t" test.

Continuous data is expressed in form of proportion.

Difference in proportion is analyzed with chi square test.

Level of significance is analyzed at 95% confidence interval.

Pearson correlation is used to evaluate the linear correlation between LVEDP and LVEF.

## RESULTS -

Outcomes were assessed at 30 day and 6 month after primary PCI.

Net adverse clinical events:-

- ☐ Death all cause cardiac and non cardiac

☐ Pulmonary edema  
 ☐ Cardiogenic shock  
 ☐ Re infarction

☐ Stroke  
 ☐ Major bleeding  
 ☐ Stent thrombosis

### • Baseline characteristic and LVEDP

	LVEDP(<18 mmHg) n=62	LVEDP(>18 mmHg) n=38	P value
Age (years)	56±8.2	60±10.1	0.07
Sex (m/f)	50(80.6)/12(19.3)	30(84.2)/8(15.7)	0.18
BMI(Kg/m <sup>2</sup> )	27±1.6	27.2±1.4	0.16
HTN	30(48)	16(42)	0.78
DM	10(16)	12(19)	0.05

Table 1

	LVEDP(<18mmHg) n=62	LVEDP(>18mmHg) n=38	P value
Smoking	30(48)	14(36)	0.68
Hb(g/dl)	14.6±1.4	14.2±1.6	0.78
Creatinine clearance(ml/min)	91.1±16.3	88.6±15.7	0.06
Door to balloon time(min)	68±18.6	72±20.1	0.04
Killip class(II-IV)	3(4.8)	6(15.7)	0.005
LVEF(%)	42±6.8	38±5.8	0.001

Table 2

	LVEDP(<18mmHg) n=62	LVEDP(>18mmHg) n=38	P value
Angiographic characteristic:			0.001
SVD	36	6	
DVD	18	20	
TVD	6	8	
LM	2	4	
PROX. LAD	11	18	
Procedural characteristic:			
No. Of vessels treated	1.0±0.2	1.0±0.2	0.57
No. of lesions treated	1.1±0.4	1.1±0.5	0.68
No. of stents implanted	1.5±0.9	1.5±0.8	0.19
TIMI flow			.003
0/1	9(14.5)	12(31)	
2/3	53(85.5)	26(69)	

Table 3

• Follow up study at 30 days:


	LVEDP(<18mmHg) n=62	LVEDP(>18mmHg) n=38	P value
Death all cause		3	
Cardiac	-	3	0.005
Non cardiac	-	-	
Pulmonary edema	-	2	0.04
Re infarction in same territory	-	3	0.05
Re infarction in other territory	-	-	-
Stroke	-	-	-
Bleeding	-	-	-
Stent thrombosis	-	3	0.001

Table 4


• Follow up study at 6 months:

	LVEDP(<18mmHg) n=62	LVEDP(>18mmHg) n=38	P value
Death all cause	1	6	
Cardiac	-	6	0.001
Non cardiac	1	0	
Pulmonary edema	1	3	0.05
Re infarction in same territory	-	3	0.04
Re infarction in other territory	-	2	0.04
Stroke	-	2	0.05
Bleeding	-	-	-
Stent thrombosis	-	3	0.001

Table 5



GRAPH 1



GRAPH 2

Of 100 patients enrolled in this study, LVEDP and EF were measured during the index event. Median LVEDP was measured which was 18 mmHg. Baseline clinical, angiographic and procedural data were stratified by median LVEDP and divided in two groups.

Patients with LVEDP >18 mm Hg compared to those with LVEDP <18 mm Hg had more diabetes, pulmonary edema, higher Killip class and lower LVEF, higher door-to-balloon time, more culprit left anterior descending coronary artery disease, and were more likely to have baseline TIMI grade 0/1 flow on presentation.

There were no significant differences in number of lesions and vessels treated.

Of patients undergoing PCI, TIMI grade 3 flow was established slightly less frequently in patients with LVEDP >18 mm Hg compared to those with LVEDP <18 mm Hg (85.5% vs 69%,  $p = 0.003$ ).

Patients with LVEDP >18 mm Hg were also more likely to have increase in serum creatinine with decrease in creatinine clearance ( $p = 0.06$ ).

Patients with LVEDP >18 mm Hg had significantly higher unadjusted rates of death, reinfarction, pulmonary edema, stent thrombosis at 30 days and 6 month.

Mortality was higher in those with an LVEDP > 18 mm Hg ( $p = 0.0001$ ).

Linear regression analysis demonstrated a very weak correlation between LVEDP and LVEF ( $R^2 = 0.02$ ,  $p = 0.094$ ).

Stratified by medians, 6 month rates of death or reinfarction in patients with LVEF >40% and

LVEDP < 18 mm Hg, LVEF >40% and LVEDP >18 mm Hg, LVEF < 40% and LVEDP < 18 mm Hg, and LVEF <40% and LVEDP >18 mm Hg were 7.4%, 9.1%, 12.3%, and 15.8%, respectively ( $p = 0.01$ ).

## DISCUSSION-

The present study demonstrates that increased LVEDP is strongly associated with death, reinfarction, pulmonary edema, and stent thrombosis after primary PCI and is an independent predictor of death or reinfarction or stent thrombosis after primary PCI in patients with STEMI, even after adjustment for baseline LVEF.

One of the earliest signs of acute ischemia is diastolic dysfunction and LVEDP may be increased in the presence of ischemia with normal LVEF<sup>18,19,20,21,22,23</sup>

Moreover, ischemia with subsequent impairment of myocardial contractility is associated with increased LVEDP because of an upward shift of the EDP point in the pressure-volume loop. Patients with increased LVEDP also frequently had other high-risk characteristics including diabetes, previous pulmonary edema and higher Killip class on presentation, and an occluded left anterior descending coronary artery infarct.

The prognostic utility of LVEDP measurement persisted after adjustment for baseline variables. As expected, systolic dysfunction was also more common in patients with an increased LVEDP. However, and perhaps surprisingly, there was only a weak inverse correlation between LVEF and LVEDP measured concomitantly.<sup>24,25,26,27</sup>

Thus, indexes of systolic and diastolic functions during STEMI in patients undergoing primary PCI provide independent and complementary prognostic information.

It has previously been shown that LVEF measured during the index procedure in patients with STEMI undergoing primary PCI is an important determinant of early and late mortality. Left ventriculography also provides potentially critical information on regional wall motion and may identify unexpected mechanical complications of STEMI. However, some operators do not perform left ventriculography during primary PCI because of concerns of delay to reperfusion, contrast nephropathy, hypotension, and ventricular arrhythmias. Measurement of LVEDP avoids these risks and, although not possessing all the prognostic utility of LVEF, is still an independent correlate of early and late death or reinfarction. There are several possible explanations for the association between increased LVEDP and subsequent death or reinfarction. Myocardial perfusion is driven by the diastolic pressure gradient between aortic and LV pressures, which determine endocardial capillary pressure. The fact that TIMI grade 3 flow was established less commonly in patients with increased LVEDP in this study is therefore not unexpected and likely contributed the poor prognosis in these patients. Moreover, myocardial perfusion is inversely proportional to LVEDP.

In consequence, even after successful reperfusion of the epicardial coronary artery, high LVEDP results in decreased perfusion pressure, impaired microvascular flow and subendocardial oxygen delivery, an sympathetic and neurohormonal activation resulting in pathologic myocardial remodeling.

Pulmonary edema and increased LVEDP have been found to be associated with contrast-induced nephropathy after PCI which is strongly associated with death and reinfarction. In the present study patients with high LVEDP also had a higher rate of increased creatinine after PCI. Some patients with increased LVEDP may have concomitant previous conditions associated with relaxation abnormalities and LV hypertrophy (e.g., hypertension and diabetes) and poorly tolerate ischemia and hemodynamic changes of STEMI. Nevertheless, this study does not provide evidence for causality for the association between LVEDP and outcome and should be interpreted as hypothesis generating.

## CONCLUSION

LVEDP is useful and independent predictor of mortality and morbidity following primary percutaneous intervention irrespective of ejection fraction.

## REFERENCES

1. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Gersh BJ, O'Neill WW, Mehran R, Stone GW. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *J Am Coll Cardiol* 2005;45:1397–1405.
2. De Luca G, Suryapranata H, van 't Hof AW, de Boer MJ, Hoorntje JC, Dambrink JH, Gosselink AT, Ottervanger JP, Zijlstra F. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. *Circulation* 2004;109:2737–2743.
3. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. *Circulation* 2000;102:2031–2037.
4. Zaret BL, Wackers FJ, Terrin ML, Forman SA, Williams DO, Knatterud GL, Braunwald E. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis In Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. *J Am Coll Cardiol* 1995;26:73–79.
5. Halkin A, Stone GW, Dixon SR, Grines CL, Tcheng JE, Cox DA, Garcia E, Brodie B, Stuckey TD, Mehran R, Lansky AJ. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. *Am J Cardiol* 2005;96:325–331.
6. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S; CORE Study Investigators. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. *J Am Coll Cardiol* 2002;39:30–36.
7. Diamond G, Forrester JS. Effect of coronary artery disease and acute myocardial infarction on left ventricular compliance in man. *Circulation* 1972;45:11–19.
8. Kirtane AJ, Bui A, Murphy SA, Karmaliotis D, Kosmidou I, Boundy K, Rahman A, Pinto DS, Aroesty JM, Giugliano RP, Cannon CP, Antman EM, Gibson CM; TIMI Study Group. Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. *J Thromb Thrombolysis* 2004;17:177–184.

9. St John Sutton M. Quest for diastolic prognostic indicators of clinical outcome after acute myocardial infarction. *Circulation* 2008;117: 2570-2572.
10. Kern MJ, Christopher T. Hemodynamic rounds series II: the LVEDP. *Catheter Cardiovasc Diagn* 1998;44:70-74.
11. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med* 2008;358:2218-2230
12. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. *Am Heart J* 2008;156:44-56.
13. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald ET. TIMI frame count: a quantitative method of assessing coronary artery flow. *Circulation* 1996;93:879-888.
14. Cerisano G, Bolognese L, Buonamici P, Valenti R, Carrabba N, Dovellini EV, Pucci PD, Santoro GM, Antoniucci D. Prognostic implications of restrictive left ventricular filling in reperfused anterior acute myocardial infarction. *J Am Coll Cardiol* 2001;37:793-799.
15. Moller JE, Whalley GA, Dini FL, Doughty RN, Gamble GD, Klein AL, Quintana M, Yu CM. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. *Circulation* 2008;117: 2591-2598.
16. Shanks M, Ng AC, van de Veire NR, Antoni ML, Bertini M, Delgado V, Nucifora G, Holman ER, Choy JB, Leung DY, Schalij MJ, Bax JJ. Incremental prognostic value of novel left ventricular diastolic indexes for prediction of clinical outcome in patients with ST-elevation myocardial infarction. *Am J Cardiol* 2010;105:592-597.
17. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. *Circulation* 1999;99:1972-1977.
18. Van Herck PL, Carlier SG, Claeys MJ, Haine SE, Gorissen P, Miljoen H, Bosmans JM, Vrints CJ. Coronary microvascular dysfunction after myocardial infarction: increased coronary zero flow pressure both in the infarcted and in the remote myocardium is mainly related to left ventricular filling pressure. *Heart* 2007;93:1231-1237.
19. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. *Circulation* 2000;101:2981-2988.
20. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. *JAMA* 2008;300:1038-1046.
21. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004;44:1393-1399.
22. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *Am J Cardiol* 2005;95:13-19.
23. Gruberg L, Mintz GS, Mehran R, Dangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. *J Am Coll Cardiol* 2000;36:1542-1548.
24. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation* 2002;105:2259-2264.
25. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. *JAMA* 2004;292:1555-1562.
26. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. *Am J Cardiol* 2003;92:930-935.



27. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. *Am J Cardiol* 2007;100:1364–1369.